Diabetes, Hypertension, Obesity
Conditions
Keywords
Hypertension, Abdominal obesity, Diabetes, Treatment
Brief summary
Recent studies have shown that obese people are more prone to high blood pressure. With the co-existence of obesity, hypertension and diabetes, patients were more susceptible to hyperlipidemia, coronary and cerebral atherosclerosis and peripheral vascular disease. Abdominal obesity has often accompanied by substantial accumulation of visceral fat, which increased secretion of many inflammatory mediators, cytokines and adipocytokines and played an important role in cardiovascular and metabolic disease. Some reports had shown that angiotensin II receptor blockers (ARB) may improve metabolic profiles in patients with diabetes or metabolic syndrome, in addition to its hypotensive effect. It has been reported that some ARB, such as telmisartan and candesartan, can prevent weight gain and high-fat-induced obesity in experimental animals. However, whether telmisartan intervention on improvement of fat deposition and other related metabolic profiles is better than a CCB drugs (amlodipine) in those obese hypertensive patients with diabetes, was still unknown.
Interventions
DRUGAmlodipine
Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
DRUGTemisartan
Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
Sponsors
Third Military Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Information Consent Signed * Aged 30\ 70 years * For whom without anti-hypertensive therapy in 2 weeks：140mmHg≤SBP\<180mmHg，或90mmHg≤DBP\<110mmHg. For whom with anti-hypertensive therapies in 2 weeks：SBP\<180mmHg, 且DBP\<110mmHg * Waist circumference higher than 90cm in men, 80cm in women * Diagnosed diabetes
Exclusion criteria
* Grade 3 hypertension: SBP≥180mmHg, or DBP≥110mmHg * Waist circumference less than 90cm in men, 80cm in women * Known allergy or hypersensitivity to trial drugs * NYHA grade Ⅱ\ Ⅳ heart failure, Myocardial infarction or cerebrovascular accident in 1 year preceding the trial * Acute infections, tumor, severe arrhythmia, mental disease, drug or alcohol abuse * History of hepatitis or cirrhosis * History of severe kidney disease * Pregnant, lactation * Enrolled in other trials in 3 months * Any obstacles of follow-up or compliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood Pressure | Baseline, 24 weeks(End of trial) |
| Metabolic profiles, including lipid profile and blood glucose | Baseline, 24 weeks(End of trial) |
Secondary
| Measure | Time frame |
|---|---|
| Abdominal fat assessed by CT | Baseline, 24 weeks(End of trial) |
| Obesity parameters, including waist circumference (WC) and body mass index (BMI) | Baseline, 24 weeks(End of trial) |
| Incidents of side effects between groups | Baseline, 24 weeks(End of trial) |
Countries
China
Outcome results
None listed